Clinical Study

A Randomized Phase III Trial Of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin For Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Posted Date: Mar 7, 2017

  • Investigator: Elizabeth Shaughnessy
  • Co-Investigator: Sarah Elizabeth Figueira
  • Specialties: Breast Cancer, Hematology/Oncology, Oncology, Cancer, Surgical Oncology
  • Type of Study: Drug

The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin. The addition of carboplatin

Criteria:

To Be Eligible To Participate, Patients Must Have A Type Of Breast Cancer That Is Her2-Negative And Is Not Sensitive To Hormone Treatment And Have Already Been Treated With Surgery.

Keywords:

Triple Negative, Breast, Node Negative/Positive, Nrg-Br003, Cancer

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.